India’s biopharmaceutical company Biocon’s biosimilar insulin glargine got regulatory approval by the Ministry of Health Labour and Welfare (MHLW) of …

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in Market Entry

Market Entry

Breast Milk Sugar, ‘2′-fucosyllactose’ Received Approval for Infants in Europe

Breastfeeding is highly recommended by the doctors across the world. Breast milk harnesses the ideal nourishment for the infant that ...

Market Entry

First Herceptin Biosimilar Approved in Europe for Breast Cancer

UPDATE: Samsung Bioepis’ Ontruzant® (SB3)– a biosimilar to Roche’s breast cancer blockbuster drug Herceptin® (trastuzumab) has received marketing approval in ...

Market Entry

GlaxoSmithKline Wins FDA Approval for Shingles Vaccine “Shingrix”

UPDATE: US FDA approved the GlaxoSmithKline‘s shingles vaccine candidate, Shingrix™ for the prevention of shingles in adult patients aged 50 ...

Market Entry

New Drug to treat HIV-1 in Adults and Teens Received European Approval

Janssen’s Symtuza® received approval in the European Union to treat adults or adolescents aged 12 years and older with human ...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?


Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply